Vistin Pharma ASA announced preliminary earnings and production results for the fourth quarter and full year 2016. Total revenue and income was NOK 93.5 million against NOK 104.5 million a year ago. Preliminary adjusted EBITDA for the fourth quarter 2016 is negative NOK 1.8 million, compared to NOK 4.3 million in the same quarter of 2015. The adjusted results for the fourth quarter include an impact of approximately NOK 5.1 million from the lower volumes available for sale, caused by the temporary stop in production of metformin. Excluded from adjusted EBITDA for the quarter is a NOK 5.8 million provision for redundancies relating to the ongoing CMO cost savings programme, and NOK 1.7 million in one-off costs relating to the reactor failure. Preliminary LBITDA was NOK 9.3 million against preliminary EBITDA of NOK 13.0 million a year ago.

Preliminary adjusted EBITDA for the full year of NOK 29.2 million, compared to NOK 19.2 million in 2015. Total revenue and income was NOK 394.6 million against NOK 227.9 million a year ago. Preliminary EBITDA was NOK 21.7 million against NOK 27.9 million a year ago.

The total actual sales volume of metformin API for the fourth quarter was 613MT, compared to 608MT in the same quarter of 2015.

For the full year actual sales volume was 2,784MT, compared to 2,799MT last year.